MASH

CONSHOHOCKEN, Pa., July 13, 2026 Madrigal Pharmaceuticals announced that the U.S. Patent and Trademark Office (USPTO) has issued three...

CAMBRIDGE, Mass. | July 9, 2026 MetaVia Inc., a clinical-stage biotechnology company focused on developing innovative therapies for cardiometabolic...

Lille, France; Cambridge, Massachusetts, United States; and Zurich, Switzerland, July 2, 2026 GENFIT announced that U.S. Medicare has approved...

CAMBRIDGE, Mass., June 24, 2026 Wave Life Sciences announced the initiation of the Phase 2a multidose portion of the...

INDIANAPOLIS, Ind., June 18, 2026 Elanco Animal Health Incorporated has announced plans to establish Elanco Ventures, a dedicated corporate...

SINGAPORE and SEOUL, South Korea, June 17, 2026 D&D Pharmatech and HistoIndex have announced encouraging new findings from an...

NEW ORLEANS, June 8, 2026 insitro announced new preclinical findings from its lead metabolic dysfunction-associated steatohepatitis (MASH) program, demonstrating...

INGELHEIM, Germany – June 7, 2026 Boehringer Ingelheim has reported positive Phase III results for its investigational glucagon/GLP-1 dual...

COPENHAGEN, Denmark, June 7, 2026 Zealand Pharma A/S announced that its partner Boehringer Ingelheim presented detailed results from the...

SEATTLE and SINGAPORE, May 27, 2026 Callio Therapeutics has announced the presentation of its Phase 1 clinical trial design...